Having trouble viewing this email? View in your browser.
ESCMID Logo

9 May 2017
WEEKLY NEWS

Dear colleagues,

In a comment in Nature experts including CÚline Pulcini, secretary of ESGAP, urge to replace the term antimicrobial resistance with drug-resistant infection.

Your ESCMID communications editors

 

TAE Trainees Day at ECCMID 2017 was a success for trainees and experts!

After the winners of this year’s TAE awards received their prizes the Young Investigator Awardees shared some of their career experiences. The special round-table session organized by the Trainees Association of ESCMID in Vienna was a great success. New initiatives such as longer times with moderators and free participation by local medical students combined with our usual format contributed to the session's success. Read an experience report and have a look at the gallery!

› Read more
 

CMI highlight: antipseudomonal beta-lactams in febrile neutropenia

Researchers from Japan compared the effectiveness and safety of empiric antipseudomonal beta-lactam monotherapy for febrile neutropenia. The meta-analysis of 50 studies with 10,872 patients showed that imipenem/cilastatin showed the highest odds of treatment success without modification and that ceftazidime in comparison was related to lower treatment success rate. Imipenem/cilastatin showed the lowest odds of all-cause death, while patients treated with cefepime in comparison had a higher risk for all-cause death. The authors concluded that imipenem/cilastatin, piperacillin/tazobactam, and meropenem are reasonable first-choice medications for empiric therapy of febrile neutropenia.

› Read more
 

Register now for ESCMID vaccines conference in Dubrovnik

ESCMID is concerned that a lack of evidence-based information among healthcare providers and the lay public may undermine the efficacy of future vaccination campaigns. As part of its multidisciplinary approach to fight infections, ESCMID is committed to improve the scientific basis for vaccines and optimize their use in the healthcare setting. This conference is set to bring together leading experts who will present and debate the most recent data to develop strategies that will help protect generations to come from vaccine-preventable diseases.

› Read more
 

ECDC’s EULabCap report: progress driven by EUCAST

The ECDC published the EULabCap report, which compares levels of laboratory capabilities and capacities of EU/EEA member states in 2015. The report underpins public health surveillance and assesses risks posed by infectious diseases. Furthermore, it gives an indication on the progression towards practice standards and public health targets. Experts at the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are driving progress in the use of harmonised methods for antimicrobial drug susceptibility testing. Other advances are seen in laboratory collaboration with national and EU surveillance networks as well as participation in outbreak response.

› Read more
 

European Manual of Clinical Microbiology available at ESCMID office

 

You may order copies of the manual published by ESCMID and the French Microbiology Society (SFM) at the ESCMID Executive Office.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.